As we reported last month, there is significant progress being made in the treatments of chronic obstructive pulmonary disease (COPD), a group of debilitating diseases that includes emphysema and chronic bronchitis.
There is now another drug nearing FDA approval, which will add to the choices of therapies for COPD sufferers, and it should help with patient compliance, since it is a once-a-day single drug. Previously, COPD patients had to deal with multiple drugs and a more complicated schedule.
As we reported last month, there is significant progress being made in the treatments of chronic obstructive pulmonary disease (COPD), a group of debilitating diseases that includes emphysema and chronic bronchitis.
There is now another drug nearing FDA approval, which will add to the choices of therapies for COPD sufferers, and it should help with patient compliance, since it is a once-a-day single drug. Previously, COPD patients had to deal with multiple drugs and a more complicated schedule.